Loading
Life sciences · Journal article
Journal of Pain & Palliative Care Pharmacotherapy · October 23, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Opioids remain central to managing cancer-associated pain (CAP) but are often limited by constipation, nausea, sedation, and concerns about maladaptive use amid the ongoing opioid epidemic. Suzetrigine (Journavx), a first-in-class, non-opioid, selective NaV1.8 sodium channel inhibitor, was approved by the U.S. Food and Drug Administration in January 2025 for moderate-to-severe acute pain; its role in chronic pain syndromes such as CAP has not been established. This case series describes two patients with CAP of differing pathophysiology started on suzetrigine as an off-label adjuvant analgesic. An 80-year-old man with radicular pain from metastatic prostate cancer to bone, who had declined opioid therapy, had an Edmonton Symptom Assessment Scale (ESAS) pain score that fell from 4/10 at baseline to 1-2/10 over approximately six months, with benefit first reported after three weeks. A 63-year-old man with severe oxaliplatin-associated chemotherapy-induced peripheral neuropathy on a multidrug regimen had an ESAS pain score that improved from 9/10 to 4/10 over three weeks, during which he self-discontinued duloxetine and substantially reduced his gabapentin and oxycodone use. Neither patient experienced adverse reactions. These anecdotal cases suggest suzetrigine may have potential as an opioid- and adjuvant-sparing analgesic across more than one CAP pain phenotype, supporting further prospective study outside its currently approved acute-pain indication.